Study overview:
-
A retrospective cohort study was conducted using PurpleLab® CLEAR longitudinal claims incurred between January 1, 2019 and June 30, 2024.
-
The study cohort (N=856) included patients with at least one medical claim for multiple myeloma, lymphoma, or leukemia between January 1, 2020 and June 30, 2023.
-
The patients subsequently initiated CAR-T therapy, including idecabtagene vicleucel, lisocabtagene maraleucel, ciltacabtagene autoleucel, tisagenlecleucel, brexucabtagene autoleucel, and axicabtagene ciloleucel.
-
Patients were required to be continuously eligible to receive medical and pharmacy benefits for at least 12 months pre-diagnosis.
-
Patients were excluded from the study cohort if they were diagnosed with any primary or secondary cancer—including t-cell/NK-cell malignancy and excluding non-melanoma skin cancer—during the 12-month baseline period.
The findings underscore key attributes of the typical CAR-T patient—often not a diverse sub-population—and highlight the need for RWD to evaluate how demographics, SDOH, and treatment effects influence patient selection, complications, and treatment response.
RWD can also clarify variation in outcomes across CAR-T therapies, providing insight into differences in complications and potentially suggesting long-term effectiveness while informing more equitable patient management.
This analysis addresses a knowledge gap by providing product-specific safety and survival data that extend beyond the controlled environment of clinical trials, offering valuable baseline evidence to guide treatment decisions and support healthcare systems in modeling the cost-effectiveness and safety profile of these therapies.
Download the full research poster below for more detail.